Xcellbio announced today that it had granted bluebird bio, Inc., a commercial license and entered into a supply agreement for the use of Xcellbio's proprietary cell manufacturing technology, AVATARtm, ...

Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic medicines, today announced its launch, alongside its acquisition of Landmark Bio. Landmark Bio ...

The company is expanding its cardiology portfolio with a new treatment for transthyretin amyloid cardiomyopathy in Europe.

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against other best gene-editing ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) stands against other best ...

At least 63 biopharma layoff rounds were conducted in the first quarter of this year, with cell and gene biotechs accounting ...

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.

Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...

Anocca AB has secured the first regulatory authorization in Europe for a CRISPR-Cas gene-edited T-cell receptor T-cell therapy trial, with the phase I/II study now due to start over the next three ...